Elbit Imaging Ltd. (TASE: EMITF-M, OTC: EMITF) operates as a shell company with no significant current operations; it functions primarily as an investment holding entity with residual interests in real estate projects in India and medical instruments in Israel. The company, formerly known as Elbit Medical Imaging Ltd., previously developed and sold medical systems including therapeutic ultrasound treatment equipment incorporating magnetic resonance imaging for non-invasive human body treatments and stem cell expansion technologies derived from umbilical cord blood for bone marrow transplantation in leukemia, non-malignant blood diseases, and metabolic genetic conditions; it also held stakes in commercial centers, hotels such as the Radisson Blu and Park Inn in Romania and Belgium, and plots for residential development. Founded in 1996 and headquartered in Bnei Brak, Israel, Elbit Imaging maintains a minimal staff of three employees and focuses on real estate in Central and Eastern Europe as well as India, alongside dormant medical segments. Recent activities include reporting a net loss of ILS 1.82 million for the third quarter ended September 30, 2025, up from ILS 0.676 million the prior year, alongside an annual general meeting in November 2025 and ongoing note buyback programs; the company executed a 1-for-10 reverse stock split effective June 2024 and sold Elbit Medical shares to Exigent Capital for $5 million in a prior transaction, reflecting its strategy to streamline holdings post-2007 name change and historical asset disposals like the 2015 sale of Belgian hotels to KKR.